Evidence map›Paper›PMID 40140076›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

Aggressive subtypes in basal cell carcinomas might need different treatment and follow-up due to the higher risk of surgically uncontrollable recurrences.

Svenja Rebecca Sonntag, Rebecca Beach, Stefanie Gniesmer, Joyce Tohme, Salvatore Grisanti, Armin Mohi, Sara Hsin-Yi Yang, Vinodh Kakkassery

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Svenja Rebecca SonntagDepartment of Ophthalmology, University of Lübeck, Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. Svenja.sonntag@uksh.de.
Rebecca BeachDepartment of Ophthalmology, University of Lübeck, Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Stefanie GniesmerDepartment of Ophthalmology, University of Lübeck, Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Joyce TohmeDepartment of Ophthalmology, University of Lübeck, Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Salvatore GrisantiDepartment of Ophthalmology, University of Lübeck, Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Armin MohiDepartment of Ophthalmology, University of Lübeck, Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Sara Hsin-Yi Yang *Department of Dermatology, University of Lübeck, Medical Center Schleswig-Holstein, 23538, Lübeck, Germany.
Vinodh Kakkassery *Department of Ophthalmology, University of Lübeck, Medical Center Schleswig-Holstein, Campus Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBasal cell carcinoma (BCC) is the most frequent malignant tumor of the eyelid and recurrences of BCC may lead to massive destruction of the orbital region. The objective of this study was to evaluate predictors for surgically difficult-to-control or uncontrollable recurrences.

methodsAll BCCs of the periorbital region treated in the Department of Dermatology or Ophthalmology between 2011 and 2021 were included in a retrospective single center study and divided into a group of primary BCCs (pBCCs) and a group of recurrent BCCs (rBCCs). The following risk factors were compared between the two groups using the Chi

resultsData from 474 pBCCs and 33 rBCCs were included in this retrospective analysis. Both R1 status (p < 0.001) and aggressive subtype (p = 0.028) were significant risk factors for recurrence. The two most frequent reasons for R1 were the patient's rejection of further surgical intervention (n = 4) and the fact that the surgery was not performed at a specialized center (n = 6). In 10 of the 33 rBCCs, a further recurrence occurred despite R0 status and all 10 cases showed an aggressive subtype (p = 0.020). In all BCCs with R1 status, there was no significant difference in the recurrence rate regarding the subtype.

conclusionOur results show the impact of incomplete tumor resection and aggressive subtype on patient outcome after BCC surgery. We suggest that the aggressiveness of the BCC may be the precondition for multiple recurring BCCs. Furthermore, especially patients who underwent surgery outside our Departments showed R1 situations and rBCCs. Therefore, personalized treatment and follow-up care as well as efforts to avoid high-risk recurrences with aggressive subtypes are necessary to improve long-term success after surgery and should be conducted by a specialized center.

Indexed as

Basal Cell CarcinomaEyelid NeoplasmsNeoplasm Recurrence, LocalOphthalmologic Surgical ProceduresSkin NeoplasmsAdultAgedAged, 80 and overFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesRisk FactorsAggressive subtypeBasal cell carcinomaBCCEyelid tumorRecurrence

Identifiers

PMID40140076
PMCPMC12373693

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.